|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||52.99 - 53.49|
|52 Week Range||33.93 - 59.40|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||113.35|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||0.40 (0.75%)|
|1y Target Est||59.29|
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.
Moody's Investors Service ("Moody's") affirmed Dentsply Sirona Inc.'s senior unsecured rating at Baa2 and its commercial paper rating at Prime-2. Moody's revised the company's outlook to stable from negative. The outlook revision reflects Moody's expectations that the company's efforts to reduce costs will lead to sustained improvement in operating margins.
Food delivery firm Grubhub, industrial heavyweight 3M and consumer products giant Colgate Palmolive are all prime targets for activist investors.
The dental solutions provider didn't meet analysts' revenue expectations in Q2 but achieved significant bottom-line improvement.
Dentsply (XRAY) delivered earnings and revenue surprises of 6.45% and -2.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Reported Q2 revenues of $1,009.4 million, declined 3.1% versus prior year and increased 3.0% on an internal sales growth basis.Q2 2019 US GAAP EPS of $0.16 vs. $(4.98) in Q2.
Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.